Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• Perspective Therapeutics, Inc. (NYSE:CATX) has received an average rating of "Buy" from eleven brokerages, with one hold, seven buy, and three strong buy recommendations.
• The average twelve-month price target set by analysts for the company is $12.56, with notable price target increases from several firms.
• The company's stock has shown significant volatility, with a 52-week low of $1.60 and a high of $16.31, currently trading around $3.36.

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has earned an average recommendation of "Buy" from the eleven ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $12.5556.

Several analysts recently commented on CATX shares. Truist Financial cut their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Royal Bank Of Canada raised shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and increased their price objective for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. Finally, B. Riley reissued a "buy" rating and set a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd.

Perspective Therapeutics Stock Down 2.3%

Shares of Perspective Therapeutics stock traded down $0.08 during trading on Monday, hitting $3.46. The company's stock had a trading volume of 2,005,476 shares, compared to its average volume of 926,789. The company has a fifty day simple moving average of $3.75 and a two-hundred day simple moving average of $2.98. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $16.31.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently bought and sold shares of CATX. Millennium Management LLC purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $4,132,000. Nuveen LLC purchased a new stake in shares of Perspective Therapeutics during the 1st quarter valued at about $2,647,000. Affinity Asset Advisors LLC boosted its holdings in shares of Perspective Therapeutics by 71.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock valued at $4,738,000 after acquiring an additional 924,196 shares during the last quarter. Octagon Capital Advisors LP boosted its holdings in shares of Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock valued at $7,352,000 after acquiring an additional 882,528 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Perspective Therapeutics during the 4th quarter valued at about $2,075,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.